CervoMed Inc. Logo

CervoMed Inc.

Developing CNS therapeutics for neurodegenerative diseases like dementia with Lewy bodies.

CRVO | US

Overview

Corporate Details

ISIN(s):
US2537484048 (+1 more)
LEI:
Country:
United States of America
Address:
20 PARK PLAZA, 2116 BOSTON
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

CervoMed Inc. is a clinical-stage biotechnology company focused on developing treatments for age-related, neurodegenerative diseases. The company advances central nervous system (CNS) therapeutics by targeting synaptic dysfunction, the reversible aspect of the neurodegenerative process, in the early stages of disease. Its lead investigational product is neflamapimod, an orally administered, small molecule brain penetrant that inhibits the p38 alpha protein kinase. CervoMed is advancing neflamapimod through clinical trials, including a Phase 2 study for patients with dementia with Lewy bodies (DLB).

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-04 13:08
Regulatory News Service
8-K - CervoMed Inc. (0001053691) (Filer)
English 80.6 KB

Automate Your Workflow. Get a real-time feed of all CervoMed Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for CervoMed Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for CervoMed Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Mereo BioPharma Group plc Logo
A clinical-stage biopharma developing and commercializing novel therapies for rare diseases.
United States of America MREO
Mersana Therapeutics, Inc. Logo
Developing innovative antibody-drug conjugates using proprietary platforms to treat cancer.
United States of America MRSN
Merus N.V. Logo
Develops multispecific antibody therapies that harness the immune system to fight cancer.
United States of America MRUS
MESOBLAST LTD Logo
Develops off-the-shelf cellular medicines for complex inflammatory and chronic diseases.
United States of America MESO
Metagenomi, Inc. Logo
Discovering novel gene editing tools from nature for curative genetic medicines.
United States of America MGX
MetaVia Inc. Logo
A clinical-stage biotech developing novel drugs for cardiometabolic diseases like obesity and MASH.
United States of America MTVA
Metsera, Inc. Logo
Develops potent, long-acting oral & injectable therapies for obesity & metabolic diseases.
United States of America MTSR
Mezzion Pharma Co., Ltd. Logo
Develops and out-licenses novel therapeutics like udenafil, with a focus on rare diseases.
South Korea 140410
MFC Co., Ltd. Logo
A GMP-certified CDMO/CMO developing and manufacturing APIs for the global pharma sector.
South Korea 432980
Milestone Pharmaceuticals Inc. Logo
Developing a self-administered nasal spray for at-home treatment of acute cardiac events.
United States of America MIST

Talk to a Data Expert

Have a question? We'll get back to you promptly.